LAS VEGAS, June 25, 2024 /PRNewswire/ -- JanOne Inc.
(Nasdaq: JAN), a multidisciplinary organization with a focus on
healthcare and fintech, announced today that its wholly-owned
subsidiary, ALT5 Sigma, has launched its prepaid VISA®️
Card as an extension to the previously announced ALT5 Settlement
Platform.
ALT5 continues to expand its digital fintech offering in the
crypto world to provide functionality from traditional
legacy financial models in a modernized world. The addition
of an unbranded prepaid Visa®️ Card provides
institutions and merchants with the ability to utilize the ALT5
suite of offerings for acceptance and conversion of
crypto to fiat and then gain instantaneous access to
fiat currencies on their prepaid VISA®️ Card or on
thousands of cards as applicable.
"Many of our customers are looking for efficient ways to access,
distribute and spend fiat derived from their crypto
strategies. The addition of the ALT5 prepaid
VISA®️ Card offering broadens their options and
continues to bridge legacy financial products to the digitization
of currency. Our customers can utilize a reloadable,
physical, and/or digital prepaid VISA®️ Card for
themselves, or for their own end-users. The integration to
ALT5 Settlement enables customers with the ability for them to deal
with multi-currencies, including fiat and crypto, and
to convert funds directly to their card 24 hours a day, 7 days
week, and 365 days a year," commented Andre
Beauchesne, President and CEO of ALT5 Sigma.
About ALT5 Sigma Inc.
Launched in 2018, ALT5 is a fintech company that provides next
generation blockchain-powered technologies to enable a migration to
a new global financial paradigm. ALT5, through its
subsidiaries, offers two main platforms to its customers: "ALT5
Pay" and "ALT5 Prime". The Company processed over
US$1.2 billion in
cryptocurrency transactions in 2023.
ALT5 Pay is a crypto-currency payment gateway that
enables registered and approved global merchants to accept and make
crypto-currency payments or to integrate the ALT5 Pay
payment platform into their application or operations using the
plugin with WooCommerce and or ALT5 Pay's checkout widgets and
APIs. Merchants have the option to convert to fiat
currency(s) automatically or to receive their payment in digital
assets.
ALT5 Prime is an electronic over-the-counter trading platform
that enables registered and approved customers to buy and sell
digital assets. Customers can purchase digital assets with
fiat and, equally, can sell digital assets and receive fiat.
ALT5 Prime is available through a browser-based access mobile phone
application named "ALT5 Pro" that can be downloaded from the Apple
App Store, from Google Play, through ALT5 Prime's FIX API, as well
as through Broadridge Financial Solutions' NYFIX gateway for
approved customers.
About JanOne
JanOne is a unique Nasdaq-listed multidisciplinary organization
with a focus on healthcare and fintech. JanOne is one of the
constituents of the Russell Microcap Index, starting June 28, 2024. Through its biotech
activities, JanOne is developing innovative, actionable solutions
intended to help end the opioid crisis. JanOne is dedicated
to funding resources toward innovation, technology, and education
to find a key resolution to the national opioid epidemic, which is
one of the deadliest and most widespread in the nation's
history. Its drugs in the clinical trial pipeline have shown
promise for their innovative targeting of the causes of pain as a
strategic option for physicians averse to exposing patients to
addictive opioids.
JanOne's ALT5 subsidiary is a global fintech that provides next
generation blockchain powered technologies for the trading,
clearing, settlement, payment, and custodianship of digital
instruments.
Please visit www.janone.com for additional information.
Forward Looking Statements
This press release contains statements that are forward-looking
statements as defined within the Private Securities Litigation
Reform Act of 1995, including, but not limited to, statements
relating to the statements that JAN 101 will treat PAD, that JAN
123 will treat CRPS, the timing of the commencement of clinical
trials, that the FDA will permit approval through a 505(b)(2)
pathway for JAN 123, that upon approval JAN 101 will immediately
disrupt the PAD market, and other statements, including words such
as "continue", "expect", "intend", "will", "hope" "should",
"would", "may", "potential", and other similar expressions. This
press release also contains statements and links relating to the
profitability and prospective growth of ALT5's platforms and
business, including, but not limited to international currency
risks, third-party or customer credit risks, liability claims
stemming from ALT5's services, and technology challenges for future
growth or expansion. Such statements reflect JanOne's current
view with respect to future events, are subject to risks and
uncertainties, and are necessarily based upon a number of estimates
and assumptions that, while considered reasonable by JanOne, are
inherently subject to significant business, economic, competitive,
political, and social uncertainties and contingencies.
Many factors could cause JanOne's actual results, performance,
or achievements to be materially different from any future results,
performance or achievements described in this press release.
Such factors could include, among others, those detailed in the
Company's periodic reports filed with the Securities and Exchange
Commission (the "SEC"). Should one or more of these risks or
uncertainties materialize, or should the assumptions set out in the
section entitled "Risk Factors" in JanOne's filings with the SEC
underlying those forward-looking statements prove incorrect, actual
results may vary materially from those described herein.
These forward-looking statements are made as of the date of this
press release and JanOne does not intend, and does not assume any
obligation, to update these forward-looking statements, except as
required by law. JanOne cannot assure that such statements
will prove to be accurate as actual results and future events could
differ materially from those anticipated in such statements.
Individuals are cautioned that forward-looking statements are not
guarantees of future performance and accordingly investors are
cautioned not to put undue reliance on forward-looking statements
due to the inherent uncertainty therein.
Media Contact Investor Relations
IR@janone.com
1-800-400-2247
View original content to download
multimedia:https://www.prnewswire.com/news-releases/alt5-sigma-a-janone-company-adds-prepaid-visa-card-integration-to-alt5-settlement-platform-302180946.html
SOURCE JanOne Inc.